Stammdaten
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Unternehmen & Branche
| Name | Neuphoria Therapeutics Inc. |
|---|---|
| Ticker | NEUP |
| CIK | 0001191070 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Medical - Pharmaceuticals |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 28,3 Mio. USD |
| Beta | 0,48 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | 1,864,092 | -0.77 | 36,598,302 | 29,700,824 | |
| 2025-09-30 | 10-Q | -9,906,504 | -4.41 | 27,343,913 | 12,510,187 | |
| 2025-06-30 | 10-K | 15,649,448 | -369,632 | -0.23 | 28,589,614 | 19,002,574 |
| 2025-06-30 | 10-Q | -400,000 | 28,589,614 | 19,002,574 | ||
| 2025-03-31 | 10-Q | 15,000,000 | 11,262,161 | 6.55 | 30,713,319 | 25,997,308 |
| 2024-12-31 | 10-Q | 662,715 | -1,943,349 | -1.79 | 18,168,220 | 13,747,995 |
| 2024-09-30 | 10-Q | -804,787 | -0.62 | 22,917,207 | 17,070,364 | |
| 2024-06-30 | 10-K | -15,492,166 | -18.62 | 27,649,093 | 17,490,372 | |
| 2024-06-30 | 10-Q | -15,500,000 | 27,649,093 | 17,490,372 | ||
| 2024-03-31 | 10-Q | -2,778,148 | -2.83 | 17,945,737 | ||
| 2023-12-31 | 10-Q | -4,554,424 | -5.31 | 19,497,443 | ||
| 2023-09-30 | 10-Q | -5,472,568 | 0.00 | 17,227,512 | ||
| 2023-06-30 | 10-K | -21,381,677 | -0.02 | 28,562,948 | 22,010,563 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-10-21 | Lynx1 Capital Management LP | 10% Owner | Open Market Purchase | 639,110 | 5.14 | 3,283,108.07 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.